SCHEMBL21596799

SCHEMBL21596799

COc1cc(COCC(F)(F)F)cc(F)c1C#N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CACNA1H O95180 1/20 0.38
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 2/20 0.35
AR P10275 3/20 0.34
ALDH1A1 P00352 6/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
NR3C2 P08235 1/20 0.34
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
TACR1 P25103 1/20 0.33
HTT P42858 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21596790 0.85 ALDH1A1 (0.38) CYP3A4CYP2C19CACNA1HMAPK1KDM4E
SCHEMBL21596854 0.83 NPC1 (0.39) MAPTCYP3A4CYP2C19CACNA1HMAPK1
SCHEMBL22802480 0.79 CACNA1H (0.39) MAPTCYP3A4CYP2C19KMT2ACACNA1H
SCHEMBL12763938 0.79 PTGS2 (0.48) CYP3A4CYP2C19MEN1KMT2ACACNA1H
SCHEMBL21596827 0.77 CACNA1H (0.41) MAPTCYP3A4CYP2C19CACNA1HMAPK1
SCHEMBL15955655 0.75 CACNA1H (0.39) MAPTCYP3A4CYP2C19CACNA1HMAPK1
SCHEMBL15955546 0.75 TNKS2 (0.41) CYP3A4CYP2C19KMT2ACACNA1HMAPK1
SCHEMBL31432491 0.75 CACNA1H (0.39) MAPTCYP3A4CYP2C19MEN1KMT2A
SCHEMBL31432811 0.73 ALDH1A1 (0.42) MAPTCYP3A4CYP2C19MEN1KMT2A
SCHEMBL30545886 0.73 CACNA1H (0.44) CACNA1HALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
EP-4335439-A2 COMPOUNDS CTXT PTY LTD (AU) 2024-03-13 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
EP-3810602-B1 COMPOUNDS CTXT PTY LTD (AU) 2023-11-01 EP disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
US-20220153710-A1 Compounds CTXT PTY LTD (AU) 2022-05-19 US disclosed
EP-3810602-A1 COMPOUNDS CTXT Pty Limited (AU) 2021-04-28 EP disclosed
CN-112334466-A Compound (I) CTXT私人有限公司 2021-02-05 CN disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
US-20200039945-A1 Compounds CTXT PTY LIMITED (AU) 2020-02-06 US disclosed
WO-2019243491-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2019-12-26 WO disclosed
WO-2019243491-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153710-A1 Compounds SLC10A1, ABCB11, PCSK9 MAPT 1135/4885CYP3A4 50/4885CYP2C19 11/4885
US-20200039945-A1 Compounds SLC10A1, ABCB11, PCSK9 MAPT 1136/4885CYP3A4 50/4885CYP2C19 11/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B MAPT 2629/4885CYP3A4 329/4885CYP2C19 175/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 MAPT 1136/4885CYP3A4 50/4885CYP2C19 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.